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Meta-analysis of outcomes in laparoscopic versus open liver resection
The introduction of laparoscopic liver resection happened in the way of many other surgical procedures, that is, by
technical innovation followed by a gradual expansion of indications and types of procedure. In many ways, it is
difficult to see how such a technology could develop in any other way. Advances in laparoscopic liver resection have
not been universally welcomed. Its role in cancer in particular has been questioned. It is important therefore that
these outcomes are investigated. In this edition of HPB, Parks et al. report a meta-analysis of outcomes in patients
who underwent liver resection by laparoscopic compared with open approach. It is important to note that none of
the studies included in this meta-analysis are randomized controlled trials but are comparative studies. This is the
major limitation of this report since there is inevitably a selection bias for type of surgery despite matching.
Notwithstanding this limitation this is an important paper, which includes outcomes frommore than 1000 patients
undergoing liver resection – 45% laparoscopic and 55% open. The paper reports that 1, 3 and 5 year survival was
equivalent between the two approaches. Subgroup analysis showed no difference for patients with HCC but an
apparent survival advantage in favour of laparoscopic resection for colorectal liver metastases. To my mind, this
study makes a strong case that if patients are selected as being technically suitable to undergo laparoscopic liver
surgery, then this option should seriously be considered. Potential advantages of laparoscopic approaches in terms
of functional recovery, pain and cosmesis remain to be evaluated. Now we have the comparative meta-analysis
maybe it is time for the international randomized controlled trial?
Stephen J Wigmore
Treating synchronous colorectal cancer primary and hepatic metastases:
should the liver go first?
Hepatic surgeons are frequently asked to deal with increasingly complex decisions with regard to themanagement of
patients with colorectal liver metastases.With rectal cancer, there is the need to treat the primary with radiotherapy
prior to surgery and the duration between radiotherapy and surgery seems to be increasing.Although patients receive
a sensitising dose of chemotherapy during radiotherapy, it is usually only 5-FU based and thereforemay have limited
effect on systemic disease. Thus for patients presenting with synchronous hepatic disease, the question arises as to
whether it is safe to wait while the primary is treated or if the systemic disease be treated with chemotherapy and
hepatic surgery, followed by focused treatment of the primary. A systemic first approach has many potential
advantages such as,preventing delays in the patient receiving systemic therapy, identifying patientswith unfavourable
aggressive disease biology who will not benefit from surgical intervention and avoiding the need for synchronous
surgery if major or complex hepatic surgery is required.With these issues in mind, Lam et al. have performed a well
conducted systematic review to assess the role of the liver first approach for those patientswith synchronous colorectal
liver metastases and primary colorectal cancer in situ. The authors identified only four studies that met inclusion
criteria.These consistedof 121patients of whom120 (99%)underwentupfront chemotherapy,112 (93%)underwent
subsequent hepatic resection and 89 (74%) subsequently completed the initially proposed treatmentwith subsequent
resection of their primary. Themedian overall survival was a respectable 40months although 52% developed disease
recurrence. Each step was associated with seemingly acceptablemorbidity andmortality. Thus what can we conclude
from such data? Certainly the ‘liver first appraoch’ is possible and would appear to be safe although the level of
evidence was low and the degree of heterogeneity between studies was high. Is this the type of situation where the use
of large databases and predictive nomogramsmay bemore appropriate than a randomised controlled trial? Given the
number of potential variables that exist across such a complex treatment regimen, it is unlikely that staging or
treatment options will remain static or standardised over the duration of a randomised controlled trial.
Saxon Connor
Justifiably, a milestone in pancreas cancer care
The utility of interferon-based adjuvant chemoradiation therapy for pancreas cancer (Virginia Mason protocol –
VMP) has not been confirmed or accepted. Despite promising initial reports of 5-year survival rates exceeding 50%,
subsequent single and multi-institutional trials have failed to replicate these outcomes. Every trial however has
confirmed the brutal systemic toxicity that has plagued this protocol. Perhaps VMPmight be better tolerated before
resection? Jensen et al. report results of a Phase II trial evaluating neoadjuvant use of VMP in patients with
borderline resectable and locally-advanced pancreas cancer. Over some six years, 23 patients were enrolled but only
seven of these completed all treatments. Surgical margins were negative in all but one of the seven resections,
something often reported in neoadjuvant trials. Overall survival did improve when VMP could be combined with
resection (22.6 mo vs. 8.8 mo VMP alone). Most often, though, it just couldn’t be. Severe grade 3 or 4 systemic
toxicity occurred in 19/23 patients (83%). As expected, profound leucopoenia and gastrointestinal toxicity pre-
vailed, and one patient even died from fulminant cholangitis. Consequently, the trial was halted prematurely a full
20 patients shy of the original enrollment target of 43. Unfortunately, we have yet further proof that VMP does not
extend survival. Instead, it makes patients entering the final months of their lives terribly and unnecessarily sick.
Despite the extraordinary and noble effort behind the concept and creation of VMP, it appears little if any of its
initial promise remains. Even so, it should be regarded as a milestone in pancreas cancer care.
Mark Callery
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